Introduction: FK506 binding proteins (FKBPs) function as oncogenes or tumor suppressors by interacting with steroid hormone receptors, kinases, or other cellular factors in addition to intracellular ligands FK506 and rapamycin. In this study, we aimed at evaluating the expression and function of FKBPs in renal cell carcinoma (RCC). Materials and Methods: Thirty-four RCC specimens were analyzed by whole transcriptome sequencing. Small interfere RNA was employed to knockdown FKBP10 in 786-O and A-704 cells, and cell proliferation, cell cycle progression, invasion and migration were evaluated. Results: FKBP10 was different from other members of FKBPs with most significant upregulation in almost all RCC specimens, compared to normal mucosa. FKBP10 expression was high in additional 38 RCC specimens and RCC cell lines compared to paired non-tumor tissues and normal renal tubule cells. FKBP10 knockdown led to cell cycle arrest at G0/G1 phase, and reduced cell proliferation, invasion, and migration in 786-O and A-704 cells. In addition, heat shock protein 90 was significantly downregulated after FKBP10 knockdown. Conclusions: FKBP10 is overexpressed and promotes RCC and is a new promising biomarker and therapy target for RCC.

Keywords:
Renal cell carcinoma, FK506 binding proteins, RNA-seq, Hsp90
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2.
Sadler GJ, Anderson MR, Moss MS, Wilson PG: Metastases from renal cell carcinoma presenting as gastrointestinal bleeding: two case reports and a review of the literature. BMC Gastroenterol 2007;7:4.
3.
Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
4.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-924.
5.
Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A: Basic research in kidney cancer. Eur Urol 2011;60:622-633.
6.
Harding MW, Galat A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341:758-760.
7.
Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989;341:755-757.
8.
Kang CB, Hong Y, Dhe-Paganon S, Yoon HS: FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 2008;16:318-325.
9.
Yao YL, Liang YC, Huang HH, Yang WM: FKBPs in chromatin modification and cancer. Curr Opin Pharmacol 2011;11:301-307.
10.
Lam E, Martin M, Wiederrecht G: Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs. Gene 1995;160:297-302.
11.
Solassol J, Mange A, Maudelonde T: FKBP family proteins as promising new biomarkers for cancer. Curr Opin Pharmacol 2011;11:320-325.
12.
Kösemehmetoğlu K, Gedikoğlu G, Ruacan S: Morphological and immunohistochemical features of malignant vascular tumors with special emphasis on GLUT1, and FKBP12 expressions. Turk Patoloji Derg 2011;27:57-67.
13.
Pedersen KM, Finsen B, Celis JE, Jensen NA: muFKBP38: a novel murine immunophilin homolog differentially expressed in schwannoma cells and central nervous system neurons in vivo. Electrophoresis 1999;20:249-255.
14.
Romano S, D'Angelillo A, D'Arrigo P, Staibano S, Greco A, Brunetti A, Scalvenzi M, Bisogni R, Scala I, Romano MF: FKBP51 increases the tumour-promoter potential of TGF-beta. Clin Transl Med 2014;3:1.
15.
Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM: FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol Cell Biol 2010;30:1243-1253.
16.
De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, et al: Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci U S A 2011;108:11878-11883.
17.
Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN: FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol 2013;42:912-920.
18.
Ramadori G, Konstantinidou G, Venkateswaran N, Biscotti T, Morlock L, Galié M, Williams NS, Luchetti M, Santinelli A, Scaglioni PP, et al: Diet-induced unresolved ER stress hinders KRAS-driven lung tumorigenesis. Cell Metab 2015;21:117-125.
19.
Patterson CE, Gao J, Rooney AP, Davis EC: Genomic organization of mouse and human 65 kDa FK506-binding protein genes and evolution of the FKBP multigene family. Genomics 2002;79:881-889.
20.
Scott M, Lu G, Hallett M, Thomas DY: The hera database and its use in the characterization of endoplasmic reticulum proteins. Bioinformatics 2004;20:937-944.
21.
Guy NC, Garcia YA, Sivils JC, Galigniana MD, Cox MB: Functions of the Hsp90-binding FKBP immunophilins. Subcell Biochem 2015;78:35-68.
22.
Henriksen R, Sørensen FB, Ørntoft TF, Birkenkamp-Demtroder K: Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium. Tumour Biol 2011;32:671-676.
23.
Olesen SH, Christensen LL, Sørensen FB, Cabezón T, Laurberg S, Orntoft TF, Birkenkamp-Demtröder K: Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics 2005;4:534-544.
24.
Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A, et al: Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 2012;14:600-611.
25.
Sun Z, Dong J, Zhang S, Hu Z, Cheng K, Li K, Xu B, Ye M, Nie Y, Fan D, et al: Identification of chemoresistance-related cell-surface glycoproteins in leukemia cells and functional validation of candidate glycoproteins. J Proteome Res 2014;13:1593-1601.
26.
Guy NC, Garcia YA, Sivils JC, Galigniana MD, Cox MB: Functions of the Hsp90-binding FKBP immunophilins. Subcell Biochem 2015;78:35-68.
27.
Coss MC, Stephens RM, Morrison DK, Winterstein D, Smith LM, Simek SL: The immunophilin FKBP65 forms an association with the serine/threonine kinase c-Raf-1. Cell Growth Differ 1998;9:41-48.
28.
Isaacs JS, Xu W, Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-217.
29.
Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J, Motzer RJ: A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-546.
30.
Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003;63:917-926.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.